Washington — The American Dental Association and American Association of Oral and Maxillofacial Surgeons told federal regulators that reclassification of hydrocodone-containing combination drug products “could cause inconvenience, unnecessary suffering and higher out-of-pocket costs for patients with a legitimate need” for the medications, according to ADA News.
To read the full article, click here.
